Spero Therapeutics, Inc. (NASDAQ:SPRO)
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
Keeps a healthy share of every dollar it sells.
- Revenue
- $43.0M
- Net income
- $7.4M
- Net margin
- 17.2%
Little or no net debt.
- Total debt
- $2.0M
- Cash
- $50.8M
- Net debt / EBITDA
- -6.33x
Comfortably covers what is due within a year.
- Current assets
- $51.6M
- Current liabilities
- $8.4M
- Current ratio
- 6.12
The business funds itself from operations.
- Operating cash flow
- $19.6M
- Free cash flow
- $19.6M
- FCF margin
- 45.6%
Not funding itself by issuing shares.
- Shares outstanding
- 58.0M
- Share growth (1y)
- 3.5%
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
SPRO Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 0.00 | 258.00 K | 39.66 M | 3.05 M | 11.80 M | 5.87 M |
| Revenue Growth (YoY) | -100.00 % | -95.61 % | 163.61 % | -77.37 % | 15.74 % | 39.72 % |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13.61 M |
| Gross Profit | 0.00 | 258.00 K | 39.66 M | 3.05 M | 11.80 M | -7.73 M |
| SG&A Expense | 6.49 M | 4.89 M | 4.30 M | 4.17 M | 5.88 M | 6.82 M |
| R&D Expense | 3.43 M | 2.91 M | 5.59 M | 8.60 M | 10.67 M | 13.61 M |
| Operating Expenses | 9.93 M | 7.80 M | 8.25 M | 10.96 M | 14.25 M | 7.00 M |
| Operating Income | -9.93 M | -7.54 M | 31.41 M | -7.92 M | -2.44 M | -14.73 M |
| Pretax Income | -9.55 M | -7.20 M | 31.78 M | -7.38 M | -1.70 M | -13.87 M |
| Tax Provision | 0.00 | 0.00 | 261.00 K | 0.00 | 0.00 | 0.00 |
| Net Income | -9.55 M | -7.20 M | 31.52 M | -7.38 M | -1.70 M | -13.87 M |
| EPS (Basic) | -0.16 | -0.13 | 0.56 | -0.13 | -0.03 | -0.25 |
| EPS (Diluted) | -0.16 | -0.13 | 0.53 | -0.13 | -0.03 | -0.25 |
| Shares Outstanding | 57.97 M | 57.28 M | 56.02 M | 56.28 M | 56.03 M | 55.38 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.